You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 20208009
Dec 202037010
Jan 20212401
Feb 20211603
Mar 20214106
Apr 20211603
May 2021306
Jun 2021004
Jul 2021004
Aug 2021006
Sep 2021004
Oct 20216022
Nov 202132016
Dec 20213202
Jan 20225603
Feb 20224204
Mar 20221402
Apr 20223603
May 20223404
Jun 20222803
Jul 20221800
Aug 20225606
Sep 20222802
Oct 20221601
Nov 20221802
Dec 20221800
Jan 20231801
Feb 20233000
Mar 20232000
Apr 20233605
May 20232601
Jun 20231601
Jul 20231802
Aug 20231201
Sep 20231600
Oct 20232202
Nov 20231802
Dec 20232201
Jan 20241000
Feb 20241800
Mar 20242402
Apr 2024801
May 20243203
Jun 20241800
Jul 20241400
Aug 20242202
Sep 20242004
Oct 20242003
Nov 20241606
Dec 20242204
Jan 20251404
Feb 2025003
Apr 2025003
May 2025002
Jun 2025003
Total11430182